发明授权
US08497240B2 DPP-IV resistant GIP hybrid polypeptides with selectable properties
有权
具有可选性质的DPP-IV抗性GIP杂交多肽
- 专利标题： DPP-IV resistant GIP hybrid polypeptides with selectable properties
- 专利标题（中）： 具有可选性质的DPP-IV抗性GIP杂交多肽
-
申请号： US12377856申请日： 2007-08-17
-
公开(公告)号： US08497240B2公开(公告)日： 2013-07-30
- 发明人: Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
- 申请人： Odile Esther Levy , Alain D. Baron , Lawrence J. D'Souza , Mary Erickson , Soumitra S. Ghosh , Michael R. Hanley , Samuel Janssen , Carolyn M. Jodka , Diana Y. Lewis , Christine M. Mack , David G. Parkes , Richard A. Pittner , Christopher J. Soares , Ved Srivastava , Andrew A. Young , Thao Le
- 申请人地址： US CA San Diego US DE Wilmington
- 专利权人： Amylin Pharmaceuticals, LLC,AstraZeneca Pharmaceuticals LP
- 当前专利权人： Amylin Pharmaceuticals, LLC,AstraZeneca Pharmaceuticals LP
- 当前专利权人地址： US CA San Diego US DE Wilmington
- 代理机构： Kilpatrick Townsend & Stockton LLP
- 国际申请： PCT/US2007/018415 WO 20070817
- 国际公布： WO2008/021560 WO 20080221
- 主分类号： A61K38/00
- IPC分类号： A61K38/00 ; A61K38/16 ; A61K38/26
摘要：
The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
公开/授权文献
信息查询
IPC分类:
